Vectus Biosystems Limited (VBS:ASX)

$1.62

right-arrow Created with Sketch. 0.02 (1.25%)
MCAP $50.64M
Last trade 16.10pm 17/09/2021 20mins delayed

Latest Announcements

07/09/2021VBSVectus Biosystems Limited
07/09/2021 Price SensitivePSVBSVectus Biosystems Limited
31/08/2021VBSVectus Biosystems Limited
31/08/2021 Price SensitivePSVBSVectus Biosystems Limited
30/08/2021VBSVectus Biosystems Limited
23/08/2021 Price SensitivePSVBSVectus Biosystems Limited
30/07/2021 Price SensitivePSVBSVectus Biosystems Limited
17/06/2021 Price SensitivePSVBSVectus Biosystems Limited

Company Overview

Vectus Biosystems Limited is an Australia-based medical research and development company. The Company has developed treatments for fibrosis and high blood pressure, which include treatment for four of the diseases in the fibrotic franchise, namely heart, kidney, liver and lung disease. Its lead compound VB0004, which is aimed at treating the loss of functional tissue to fibrosis or scarring and high blood pressure. The Company has also developed a technology, Accugen for measuring the amount of Deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) in samples tested in laboratories. Using its platform technology, the Company has constructed a library of approximately 200 small molecules with varying degrees of anti-hypertensive and anti-fibrotic properties. Accugen is developed by the Company's subsidiary, Accugen Pty Limited. Accugen comprises reagents and software that quantitate quantitative polymerase chain reaction (qPCR) reactions.

VBS in the news

Vectus Biosystems (VBS) has received firm commitments from institutional and sophisticated investors…

Search Previous Announcements